拓新药业
(301089)
| 流通市值：19.35亿 | | | 总市值：27.31亿 |
| 流通股本：8964.93万 | | | 总股本：1.27亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 322,788,021.11 | 211,303,670.02 | 92,502,151.55 | 378,343,569.65 |
| 营业收入 | 322,788,021.11 | 211,303,670.02 | 92,502,151.55 | 378,343,569.65 |
| 二、营业总成本 | 366,546,973.55 | 239,261,294.13 | 103,589,969.11 | 434,776,823.75 |
| 营业成本 | 261,385,311.67 | 170,194,606.95 | 69,975,137.75 | 278,547,000.62 |
| 税金及附加 | 6,600,289.35 | 3,972,018.65 | 1,861,332.83 | 8,142,812.21 |
| 销售费用 | 8,527,772.17 | 5,187,913.05 | 2,199,418.14 | 10,408,619.08 |
| 管理费用 | 57,031,003.38 | 37,883,515.8 | 19,638,808.94 | 94,926,371.21 |
| 研发费用 | 31,531,413.12 | 21,070,246.32 | 9,423,934.92 | 42,677,886.02 |
| 财务费用 | 1,471,183.86 | 952,993.36 | 491,336.53 | 74,134.61 |
| 其中:利息费用 | 91,505.23 | 63,100.55 | 31,398.68 | 151,035.18 |
| 其中:利息收入 | 204,951.31 | 142,132.48 | 50,867.24 | 896,666.41 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 219,484.93 | 417,019.17 | 489,358.9 | 147,519.18 |
| 加:投资收益 | 1,624,511.29 | 947,554.85 | 266,751.32 | 4,119,715.12 |
| 资产减值损失(新) | -5,471,461.96 | -5,644,145.75 | -5,943,346.04 | -16,116,367.19 |
| 信用减值损失(新) | 592,371.23 | 1,361,736.27 | 1,628,325.21 | -12,187,875.8 |
| 其他收益 | 3,396,440.28 | 2,202,474.9 | 1,219,297.78 | 8,712,797.2 |
| 四、营业利润 | -43,397,606.67 | -28,672,984.67 | -13,427,430.39 | -71,757,465.59 |
| 加:营业外收入 | 46,049.93 | 42,054.36 | 11,921.69 | 151,838.83 |
| 减:营业外支出 | 50,565.67 | 48,320.51 | 44,175.16 | 779,796.05 |
| 五、利润总额 | -43,402,122.41 | -28,679,250.82 | -13,459,683.86 | -72,385,422.81 |
| 减:所得税费用 | -2,446,362.85 | -718,453.89 | -2,950,022.79 | -2,724,395.11 |
| 六、净利润 | -40,955,759.56 | -27,960,796.93 | -10,509,661.07 | -69,661,027.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -40,955,759.56 | -27,960,796.93 | -10,509,661.07 | -69,661,027.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -40,955,759.56 | -27,960,796.93 | -10,509,661.07 | -69,661,027.7 |
| 扣除非经常损益后的净利润 | -44,934,901.66 | -30,676,409.12 | -11,998,504.05 | -78,938,143.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.32 | -0.22 | -0.08 | -0.55 |
| (二)稀释每股收益 | -0.32 | -0.22 | -0.08 | -0.55 |
| 八、其他综合收益 | - | - | - | 1,317,652.71 |
| 归属于母公司股东的其他综合收益 | - | - | - | 1,317,652.71 |
| 九、综合收益总额 | -40,955,759.56 | -27,960,796.93 | -10,509,661.07 | -68,343,374.99 |
| 归属于母公司股东的综合收益总额 | -40,955,759.56 | -27,960,796.93 | -10,509,661.07 | -68,343,374.99 |
| 公告日期 | 2026-10-27 | 2026-08-28 | 2026-04-28 | 2026-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |